COMMUNIQUÉS West-GlobeNewswire

20/20 BioLabs Highlights Advantages of its Patented Protein Biomarker Technology for Multi-Cancer Early Detection in Light of Recent Studies
12/03/2026
Protein Biomarkers May Play an Important Role in Overcoming Limitations of Circulating Tumor DNA for Screening Early-Stage Cancers GAITHERSBURG, M.D., March 12, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs (Nasdaq: AIDX), an [...]
FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology
12/03/2026
HOUSTON, March 12, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of [...]
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split
12/03/2026
WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer [...]
Pelthos Therapeutics to Present at 38th Annual ROTH Conference
12/03/2026
DURHAM, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“ [...]
Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events
12/03/2026
PARAMUS, NJ, March 12, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage [...]
CDT Notes Sarborg Expansion into Rare Disease Signature Intelligence
12/03/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 12, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement from Sarborg Limited regarding the expansion of its [...]
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities
12/03/2026
Biovance, Biovance 3L, Natalin, Acelagraft, Interfyl and Centaflex licensed to NEXGEL are established commercial products widely used today in wound care, orthopedics and other indications. Three pipeline 510(k) medical [...]
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION
12/03/2026
FIRST SITE INITIATION VISIT COMPLETED IN AUSTRALIA SARASOTA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics [...]
Ultragenyx Announces Positive 36-Week Data from Phase 3 Study of DTX301 AAV8 Gene Therapy for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
12/03/2026
Statistically significant improvements in primary endpoint of ammonia control compared with placebo at 36 weeks Clinically important changes observed in patient global impression scale for overall OTC symptoms, OTC [...]
Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
12/03/2026
$106.5 million cash position as of December 31, 2025 to be further enhanced by $35 million expected from Medtronic and Ligand in Q2 2026 from previously announced transactions, as well as Haemonetics’ Vivasure [...]
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
12/03/2026
Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, metastatic, non-squamous, non-small cell lung cancer (NSCLC) despite immune [...]
Mestag Therapeutics to Present Data on Targeted LTBR Agonist MST-0312 at Cancer Immunotherapy Keystone Symposia
12/03/2026
CAMBRIDGE, United Kingdom, March 12, 2026 (GLOBE NEWSWIRE) -- Mestag Therapeutics (“Mestag”), a biotech company harnessing fibroblast immunology for the benefit of patients with inflammatory disease and cancer, [...]
Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes
12/03/2026
PONTE VEDRA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and thrombotic conditions, today [...]
Demande d’autorisation de mise sur le marché de TECVAYLI®▼ (teclistamab) en monothérapie soumise à l’EMA pour le myélome multiple en rechute ou réfractaire après au moins une ligne de traitement antérieure
12/03/2026
Application appuyée par des données de la Phase 3 renforçant les schémas thérapeutiques à base de teclistamab comme traitement standard potentiel après au moins une thérapie antérieure 1 La monothérapie par teclistamab [...]
Verano Announces $195 Million Senior Secured Term Loan Refinancing Agreement to Fund Company’s Strategic Growth Initiatives
12/03/2026
New credit facility highlights Company’s ability to access lower-cost regional bank capital and secure among the most favorable terms in the industry, including an initial 9.5% annual interest rate and prepayment [...]
Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting
12/03/2026
New clinical data from the SYMON-I study to evaluate IL-6 and organ dysfunction in sepsis patients to be presented. ACTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or [...]
Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct® Platform
12/03/2026
Companies deepen partnership to advance automated, integrated microbiology quality control LEXINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative [...]
XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
12/03/2026
EMERYVILLE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty announced today it will report fourth quarter and full year 2025 financial results on Wednesday, March [...]
DigitalOptometrics® Announces Next Evolution in Tele-Ophthalmic Care at Vision Expo East
12/03/2026
Orlando, Florida, March 12, 2026 (GLOBE NEWSWIRE) -- New partnership with Eyoto reinforces DigitalOptometrics’ leadership in delivering consistent, high-quality remote eye exams inside the clinic. Vision Expo East — [...]

Pages